Overview
Company details and contact information.
About
About Hyundai Bioscience HYUNDAI BIOSCIENCE develops and manufactures innovative anticancer therapeutics leveraging proprietary drug delivery system (DDS) technologies to enhance bioavailability and improve tumor-targeting selectivity. Our commitment to addressing unmet medical needs drives us to continuously refine our platform technologies and explore new treatment paradigms for cancer patients worldwide. (Pipeline Overview) POLYTAXEL®: A docetaxel-based, pain-free anticancer therapy designed to reduce treatment-associated discomfort. Currently in the clinical stage, with Phase 1 IND submitted in Korea. Penetrium™: An oral niclosamide-based therapy targeting ECM(extracellular matrix), aimed at eradicating resistant tumor cell populations. Undergoing preclinical development. OTX-M™: A taxane-based oral metronomic therapy intended to maintain sustained anticancer activity with potentially reduced toxicity. Also in preclinical development. By integrating cutting-edge DDS technologies with robust clinical and preclinical strategies, HYUNDAI BIOSCIENCE strives to advance the future of cancer treatment and improve patient outcomes.
- Phone
- +82 102 173 4455
- Address
- 166 Magokdong-ro, 8th Floor, Seoul 07790, South Korea | 8F, 166 Magokdong-ro, Gangseo-gu, Seoul 07790, South Korea
People
Contacts connected to this company.